Histopathology of chronic hepatitis C in relation to virus genotype

Background/aim: The natural history of hepatitis C virus (HCV) infection is variable and the factors determining the course of the illness are unclear. There are geographical variations in the distribution of different HCV genotypes, and some of them are related to the specific infection routes. Regarding our country, the dominant genotype is genotype 1b. It is unclear and still remains a question whether the distinct histopathological manifestations are related to the particular genotypes of HCV. Thus, the aim of this study was to determine whether the distinct histopathological manifestations of HCV infection might be in relation to the individual virus genotype. Methods. In this study we examined 126 patients with chronic HCV infection regarding the histopathological features, demographic data, and virus genotype. The observed groups of patients were predominantly infected with HCV genotypes 1b and 3a. Results. In this study we found that the patients infected with HCV genotype 1b had more frequently moderate or severe necroinflammatory activity of the disease, significantly higher grading score as compared with other genotypes (p < 0.0001). A higher degree of fibrosis was, also, more common in the patients infected with genotype 1b of HCV as compared with other genotypes (p < 0.05). There were no significant correlations between the necroinflammatory activity of the disease and the stage of fibrosis in 1b, 4 and mixed genotypes. Conclusion. The present data support the hypothesis that distinct genotypes of HCV are associated with the particular histopathological manifestation of the disease.

Download Full-text

Clinical and epidemiological characteristics and gene variant structure of HCV-infection in the area of the Krasnodar Territory

Epidemiology and Infectious Diseases (Russian Journal) ◽

10.17816/eid40761 ◽

2013 ◽

Vol 18 (6) ◽

pp. 8-16

Author(s):

M. G. Avdeeva ◽

V. N. Gorodin ◽

A. A. Konchakova ◽

V. A. Dubinina ◽

N. V. Kotova ◽

...

Keyword(s):

Viral Load ◽

Hepatitis C ◽

Clinical Manifestations ◽

Hcv Infection ◽

Genotype 3 ◽

Virus Genotype ◽

Hcv Genotypes ◽

Genotype 1B ◽

Genotype 2 ◽

Epidemiological Characteristics

The purpose of research - based on analysis of the clinical-epidemiologic data, the level of viral load and the prevalence of HCV genotypes to determine current consistencies and epidemiological trends of the development of HCV-infection in the area of the Krasnodar Territory. Patients and methods. Population incidence of hepatitis C in the Krasnodar Territory was studied for the period from 2004 to 2011. Clinical manifestations of the disease we evaluated on the base of a retrospective analysis of 1913 hospital records of patients with chronic hepatitis C. There were investigated the results of 19,338 qualitative PCR studies of RNA-HCV, 2041 studies for genotyping and 363 results of quantitative evaluation of RNA-HCV Results. In the Krasnodar Territory there is revealed circulation of 1a, 1b, 2, 3a HCV genotypes. In a population of genotypes 1b (48 %) and 3a (38 %) prevail. In recent years there has been visible trend to displacement of genotype 1b by the increase the incidence of genotype 3 a in a set of areas. Social Portrait of the patient with hepatitis C: a man aged 28 to 48, a city resident, a salary earner or unemployed. There were established gender peculiarities: males are more often infected with hepatitis C genotype 3a, females - genotype 1b. In most cases (65%) viremia is characterized by moderate viral load. In the studied population there is revealed the relationship between the activity of the process and infection with certain genotype. Moderate grade of hepatitis activity is significantly more frequently recorded in the disease caused by 1c and 3 a virus subtypes. Minimal activity of hepatitis is not typical for the process caused by genotype 2 and in genotype 3 a occurs much less frequently than in cases caused by genotype 1b. Conclusion. Epidemiological analysis of the incidence of hepatitis C should take into account trends in the spread of various genotypes of the virus. Hepatitis C virus genotype should be taken into account as in the forecast of the disease and in determination of the indications for antiviral therapy. The main socio-age group actively involved in the epidemic process and need for causal treatment, are young persons of working age.

Download Full-text

The distribution of hepatitis C virus genotypes in patients with hepatocellular carcinoma

Asian Journal of Medical Sciences ◽

10.3126/ajms.v10i6.25720 ◽

2019 ◽

Vol 10 (6) ◽

pp. 28-32

Author(s):

Ayfer Bakır ◽

Nuran Karabulut ◽

Sema Alaçam ◽

Barış Bakır ◽

Ali Ağaçfidan

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Hepatic Cirrhosis ◽

Genotype 1 ◽

High Association ◽

Hcv Genotypes ◽

Genotype 1B ◽

Virus Genotypes ◽

Hepatitis C Virus Genotypes ◽

Chronic Hcv

Background: Hepatic cirrhosis develops within 20-30 years in approximately 20% of individuals chronically infected with hepatitis C virus (HCV). Aims and Objective: This study aimed to determine the distribution of HCV genotypes in patients with HCV-associated HCC in our region and thus to contribute to the epidemiology of HCV. Materials and Methods: HCC patients referred to the virology laboratory for HCV genotype identification between January 2013 and April 2018 were included in this study. Genotyping of HCV was performed by a commercial reverse hybridization line probe-based assay. Results: Seventeen patients who were diagnosed with HCC and whose HCV genotypes were analyzed were included in this study. Genotype 1 was detected in all 17 patients with HCC. When evaluating subtypes of genotype 1, genotype 1b was detected in 16 (94%) of the patients. The HCV subtyping in one patient (6%) could not be performed. Conclusion: As a result, genotype 1b, one of the major risk factors for HCC, was detected in 94% of the patients included in this study. This study, consistent with the literature, shows a high association between the development of HCC and genotype 1b in patients with chronic HCV.

Download Full-text

Acute hepatitis C virus infection

Eurosurveillance ◽

10.2807/ese.13.21.18879-en ◽

2008 ◽

Vol 13 (21) ◽

Cited By ~ 14

Author(s):

W L Irving ◽

D Salmon ◽

C Boucher ◽

I M Hoepelman

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Hcv Infection ◽

Acute Hepatitis C ◽

Acute Hcv ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

The Individual ◽

Acute Hcv Infection ◽

Subsequent Risk

Around 25% of people infected with hepatitis C virus (HCV) are able to clear the infection spontaneously, while the majority become chronically infected, with a subsequent risk for the individual patient of progressive inflammatory liver disease, cirrhosis, hepatocellular carcinoma and liver-related death (Figure 1). Much is known about the epidemiology, pathogenesis, diagnosis and management of chronic HCV infection. In comparison, knowledge about acute HCV infection is patchy. In this article, we will highlight concerns relating to acute HCV infection and suggest that public health bodies responsible for managing the HCV epidemic should redirect at least some of their resources to dealing with these issues.

Download Full-text

Effectiveness of Sofosbuvir Combined with Direct Acting Antivirals in Hepatitis C Patients in a Tertiary Teaching Hospital in Qatar: A Retrospective Observational Study

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2020/v32i3130921 ◽

2020 ◽

pp. 72-80

Author(s):

Rana Moustafa Al Adawi ◽

Zainab Jassim ◽

Dina Eltayeb Elgaily ◽

Rizwan Imanullah ◽

Mohamed Izham Mohamed Ibrahim

Keyword(s):

Hepatitis C ◽

Observational Study ◽

Hcv Infection ◽

Retrospective Observational Study ◽

Genotype 3 ◽

Hcv Genotypes ◽

Direct Acting Antiviral ◽

Tertiary Teaching ◽

Chronic Hcv ◽

Direct Acting

Background: Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality. The effectiveness of sofosbuvir, as a new direct-acting antiviral (DAA) for chronic HCV infection, needs to be assessed and evaluated among patients with or without cirrhosis with all HCV genotypes. Aims: This study was conducted to determine the effectiveness of chronic HCV treatment as part of a combination therapy for all HCV genotypes in patients with or without cirrhosis. Study Design: A retrospective observational study. Methodology: All patients who received sofosbuvir treatment from the Pharmacy Department of Hamad General Hospital during a 12-month period (between 2014 and 2015) were included. Patients were observed up to 12 weeks after treatment course completion. Data were analyzed descriptively and compared using a paired t-test (alpha=0.05). Results: A total of 95 patients received sofosbuvir. All of these patients received sofosbuvir in combination with other antiviral medications. All HCV genotypes were included; 1a and 4 were the most dominant genotypes (37% and 30.5%, respectively). Half of the patients were treatment naïve. All patients achieved undetectable virus ribonucleic acid (RNA) starting from week 4 of the treatment. A sustained virological response at 12 weeks (SVR12) after completion of the treatment period was maintained in 95% of patients. Relapse was mostly observed in patients with genotype 1a (40%); no patients with HCV genotype 3 exhibited relapse. Conclusion: The SVR12 after sofosbuvir treatment was maintained in most patients, regardless of genotype, HCV complications HCV or co-administered drugs.

Download Full-text

Chronic hepatitis C virus infection: Is there a correlation between HCV genotypes and the level of viremia?

Medicinski pregled ◽

10.2298/mpns0606230d ◽

2006 ◽

Vol 59 (5-6) ◽

pp. 230-234 ◽

Cited By ~ 2

Author(s):

Dragan Delic ◽

Zorica Nesic ◽

Jasmina Simonovic ◽

Neda Svirtlih ◽

Ljubisa Dokic ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Objective Assessment ◽

Hcv Infection ◽

Hcv Rna ◽

Genotype 4 ◽

Hcv Genotypes ◽

Genotype 2 ◽

Chronic Hcv Infection ◽

Chronic Hcv

Introduction. Hepatitis C virus (HCV) RNA status and HCV genotypes have become extremely important for exact diagnosis, prognosis, duration of treatment and monitoring of antiviral therapy of chronic HCV infection. Material and methods. For the purpose of precise and objective assessment of virologic analyses, such as the determination of the number of virus copies and virus genotypes, 110 patients with chronic HCV infection were tested. Genotyping of HCV isolates and HCV RNA quantification were performed by using the PCR method. Genotype lb infection was verified in 49.1% of patients, genotype 3a infection was found in 28.2%, genotype 4 in 9.1%, genotype 2 in 4.5%, while mixed genotype infections were diagnosed in 9.1% of cases. Results. Patients infected by genotype lb had significantly higher serum HCV RNA level in relation to patients infected by other genotypes (p<0.05). Over 70% of patients infected by genotype lb had more than 2xl06 virus copies in 1 ml of blood, while in genotypes 2, 3a and 4, the percentage was 40%, 38.5% and 30%, respectively. Male patients had approximately 7.7x10.6 virus copies in 1 ml of blood, which was significantly higher in comparison with female patients (2.3xl06 copies/ml; p<0.05). Conclusion. Our results are in concordance with the results of other authors reporting that genotype lb is predominant in Europe, as well as significantly higher incidence of viremia in patients with genotype lb infection in relation to other HCV genotypes. Based on these results, we can conclude that our patients, most commonly, present with severe clinical course of chronic HCV infection and require longer treatment (48 weeks), which causes economic problems. .

Download Full-text

Clinical, Biochemical and Virological Profile of Patients with Chronic Hepatitis C Virus Infection - A Study from University Hospital in Nepal

Journal of Nobel Medical College ◽

10.3126/jonmc.v4i1.13301 ◽

2015 ◽

Vol 4 (1) ◽

pp. 32-35

Author(s):

Dipesh Gurubacharya ◽

Mohan Khadka ◽

Khadga B Shreshta ◽

Prem Khadga ◽

Sashi Sharma

Keyword(s):

Hepatitis C Virus ◽

Viral Load ◽

Hepatitis C ◽

Drug Use ◽

Injection Drug Use ◽

Hcv Infection ◽

Genotype 3 ◽

Hcv Genotypes ◽

Chronic Hcv Infection ◽

Chronic Hcv

Introduction: Hepatitis C virus (HCV) infection is a major public health challenge. It is a major cause for cirrhosis and hepatocellular carcinoma worldwide. Both the genotype and viral load of HCV determine the choice of therapy as well as outcome of therapy. The aim of this study was to evaluate clinical, biochemical and virological profile and association of HCV genotypes with viral load and liver biochemical profile.Material and Methods: This was descriptive observational study of chronic HCV infected patients who attended at the outpatient clinic of Department of Gastroenterology of TUTH, IOM from April 2013 to November 2014. During this study period 38 patients with chronic HCV infection were analyzed. Clinical profile, possible risk factors for transmission of HCV infection and liver biochemical profile were recorded. Virological profile included HCV viral load and HCV genotypes.Results: Out of 38 patients 34(89.5%) were male and 4(10.5%) were female. Injection drug use (IDU) was the most common mode for acquisition of HCV infection (55.3%). Genotype 3 was found in 21(55.26%) patients and genotype 1 was found in 17(44.74%) patients. There was no significant association between HCV genotypes and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level. And also there was no significant association between HCV viral load and different HCV genotypes.Conclusions: In our study HCV genotype 3 was the most prevalent genotype in patients with chronic HCV infection. Injection drug use was identified as most common identifiable risk factor for transmission of HCV infection. There was no significant association between different HCV genotypes and serum ALT, AST level and HCV viral load. Journal of Nobel College of Medicine Vol.4(1) 2015: 32-35

Download Full-text

Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma

Journal of Hepatology ◽

10.1016/s0168-8278(97)80137-7 ◽

1997 ◽

Vol 27 (6) ◽

pp. 959-965 ◽

Cited By ~ 87

Author(s):

Francesc X. López-Labrador ◽

Sergi Ampurdanés ◽

Xavier Forns ◽

Antoni Castells ◽

Juan C. Sáiz ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Hcv Infection ◽

Hcv Genotype ◽

Hcv Genotypes ◽

Genotype 1B

Download Full-text

Association between risk factors, basal viral load, virus genotype and the degree of liver fibrosis with the response to the therapy in patients with chronic hepatitis C virus infection

Vojnosanitetski pregled ◽

10.2298/vsp1506505v ◽

2015 ◽

Vol 72 (6) ◽

pp. 505-509 ◽

Cited By ~ 2

Author(s):

Vuk Vukovic ◽

Dejan Baskic ◽

Zeljko Mijailovic ◽

Predrag Djurdjevic ◽

Danijela Jovanovic ◽

...

Keyword(s):

Risk Factors ◽

Viral Load ◽

Hepatitis C ◽

Hcv Infection ◽

Histopathological Changes ◽

Genotype 1 ◽

Virus Genotype ◽

Chronic Hepatitis C Virus ◽

Chronic Hcv Infection ◽

Chronic Hcv

Background/Aim. Hepatitis C is an important sociomedical problem worldwide due to frequent progression to chronic disease, occurrence of liver cirrhosis and hepatocellular carcinoma. Standard pegylated interferon alfa 2a plus ribavirin therapy results in resolution of infection only in 50% of patients. The aim of this study was to determine the association of various factors with response to the therapy in patients with chronic hepatitis C virus (HCV) infection. Age and sex of patients, inoculation risk factors, histopathological changes in the liver, viral load and HCV genotype were analyzed. Methods. The study included a group of 121 patients with chronic HCV infection. The treatment was carried out 24 weeks for virus genotype 2 and 3, and 48 weeks for genotype 1 and 4. The degree of histopathological changes in the liver was determined by hematoxylin and eosin staining, whereas polimerase chain reaction was used for HCV genotyping. Results. In the group of non-responding patients genotype 1 was represented with 100%, while in the other groups, although predominantly present, its percentage was lower. Unresponsiveness to therapy and relapse of disease were associated with higher viral load and advanced fibrosis. Intravenous use of psychoactive substances, as a risk factor, was present in a high percentage in the group of patients with sustained response, while blood transfusion and dialysis were leading risk factors in the group of relapse responders and non-responders. Conclusion. The results of our study showed that the treatment outcome of chronic HCV infection was associated with baseline HCV ribonucleic acid, HCV genotype, route of infection and the degree of histopathological changes in the liver.

Download Full-text

Treatment of acute hepatitis C infection with interferon-alfa 2b monotherapy prevents development of chronic HCV infection

Gastroenterology ◽

10.1016/s0016-5085(01)82820-1 ◽

2001 ◽

Vol 120 (5) ◽

pp. A567-A567 ◽

Cited By ~ 1

Author(s):

E JAECKEL ◽

M CORNBERG ◽

T SANTANTONIO ◽

J MAYER ◽

H WEDEMEYER ◽

...

Keyword(s):

Hepatitis C ◽

Acute Hepatitis ◽

Interferon Alfa ◽

Hcv Infection ◽

Acute Hepatitis C ◽

Hepatitis C Infection ◽

Chronic Hcv Infection ◽

Chronic Hcv

Download Full-text

Genetic polymorphisms as the predictors of response to antiviral treatment in chronic hepatitis C virus infection

Orvosi Hetilap ◽

10.1556/oh.2011.29113 ◽

2011 ◽

Vol 152 (22) ◽

pp. 876-881

Author(s):

Alajos Pár

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Genetic Polymorphisms ◽

Chronic Hepatitis C ◽

Genome Wide Association Study ◽

Antiviral Treatment ◽

Hcv Infection ◽

Snp Analysis ◽

Chronic Hcv

The review discusses the genetic polymorphisms involved in the pathogenesis of hepatitis C virus (HCV) infection, that may determine the outcome of disease. In this field earlier both certain major histocompatibility complex (MHC) alleles and some cytokine gene variants have also been studied. Recently, the genome-wide association study (GWAS) and targeted single nucleotide polymorphism (SNP) analysis have revealed that a variant in the promoter region of interleukin-28B (IL-28B) gene is strongly linked to viral clearance and it may be the strongest pretreatment predictor of treatment response in chronic hepatitis C. Last year it was shown that two genetic variants leading to inosine triphosphatase deficiency protect against haemolytic anemia in patients receiving ribavirin during antiviral treatment for chronic HCV infection. Orv. Hetil., 2011, 152, 876–881.

Download Full-text